The purpose of this study is to find out what effects, good and bad, sunitinib (the study drug) has on you and on your cancer. Another purpose of this study is to find out if there are interactions between sunitinib and your anti-HIV medications. Sunitinib is an approved anti-cancer drug which has been shown to be effective in treating patients with kidney cancer and is being studied in treating a wide range of other cancers. Thus, its use in treating other cancers at this time is experimental. We do not know if it will help treat your cancer. There will be between 21 and 42 participants in this study nationwide. There will be about 3 participants at UCLA.

Inclusion Criteria:

• HIV positive men and women 18 years of age or older
• Certain kinds of cancer
• On stable antiretroviral therapy for at least 4 weeks prior to study entry
• More than 50 T-cells
• No prior treatment with sunitinib

Exclusion criteria:

• Current active opportunistic infection
• Major surgery or radiation within 3 weeks prior to study entry
• Gastrointestinal (gut) disease which would make taking oral medication difficult
• High blood pressure
• Heart attack or other heart problems within 6 months of study entry
• Currently pregnant or breastfeeding

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #09-06-009-01

If you think you might be interested in participating in this study, please contact the Recruitment coordinator at 310-557-9062 or email at CAREoutreach@mednet.ucla.edu

Return to Clinical Trials main page